HEALTH STATE UTILITY VALUES (HSUVS) MEASURED USING THE EUROQOL 5-DIMENSIONS (EQ-5D) QUESTIONNAIRE IN ADULTS WITH CHRONIC HEPATITIS C (CHC)- A SYSTEMATIC LITERATURE REVIEW (SLR)
Author(s)
Buchanan-Hughes AM, Hanman K, Langford BE, Eddowes LA
Costello Medical Consulting Ltd, Cambridge, UK
Presentation Documents
OBJECTIVES: CHC is an infectious disease that often leads to severe and life-threatening conditions. The emergence of direct-acting antivirals has resulted in health-related quality-of-life (HRQoL) becoming an increasingly important consideration when comparing therapies. The objective of this SLR was to assess HRQoL by the identification of HSUVs for individuals with CHC, to inform cost-effectiveness modelling. METHODS: MEDLINE, Embase, the Cochrane Library and EconLit were searched in February 2016. Bibliographies of SLRs, meta-analyses, economic evaluations and health technology assessments were hand-searched along with relevant congresses and the EQ-5D database. Eligible studies reported HSUVs measured by the EQ-5D questionnaire for patients of any CHC genotype and without comorbidities other than human immunodeficiency virus or hepatitis B virus. RESULTS: Database searches yielded 947 unique records, of which 18 fulfilled the inclusion criteria. Three additional records were identified through hand-searches giving a total of 21 included records. The most commonly defined health states described various treatment statuses (eg. on/off treatment or by specific regimens) and CHC-related liver conditions. HSUVs reported for the general CHC population (eg. patients with mild/moderate disease) were <0.70 in one, 0.70–0.80 in six, 0.80–0.90 in three and >0.90 in two publications. Four studies reported HSUVs by METAVIR fibrosis stage ranging from 0.67 at stages 3–4 to 0.82 at stages 0–1 for patients without sustained virologic response (SVR), and from 0.80 at stage 4 to 1.0 at stages 0–1 for patients with SVR. Patients achieving SVR tended to have higher HSUVs than non-responders. CONCLUSIONS: A variety of health states encompassing CHC-related liver conditions and treatment statuses were reported. Patients with more severe liver conditions and those who did not achieve SVR tended to have lower HSUVs implying a poorer HRQoL. The wide range of relevant health states reported will be useful to inform cost-utility models
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PIN70
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Infectious Disease (non-vaccine)